Curi Wealth Management’s Moderna MRNA Stock Holding History

Curi Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2	Closed	–	–	508
2022 Q2	$0	Hold	2	–	–	﹤0.01%	691
2022 Q1	$0	Hold	2	–	–	﹤0.01%	601
2021 Q4	$0	Buy	+2	New	+$585	﹤0.01%	560

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Curi Wealth Management's MRNA Position: Q3 2022 in Review

Curi Wealth Management sold out of Moderna (MRNA) in Q3 2022, closing a stake of 2 shares.

Curi Wealth Management first reported a position in MRNA in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

Curi Wealth Management reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
Curi Wealth Management sold 2 Moderna shares in Q3 2022.
Curi Wealth Management first reported a position in Moderna in Q4 2021 and held it in 3 quarters.
Curi Wealth Management's Moderna position peaked at $0 in Q2 2022.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Curi Wealth Management's 13F filing for Q3 2022, filed 8 Nov 2022.